US vaccines developer Moderna (Nasdaq: MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia.
Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years.
This is the second piece of good news this month for Modera, which won $590 millon from the USA’s Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of mRNA-based pandemic influenza vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze